Go Pro
NASDAQ:BOLD

Boundless Bio Q1 2026 Earnings Report

Boundless Bio logo
$2.78 0.00 (0.00%)
As of 10:45 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Boundless Bio EPS Results

Actual EPS
-$0.60
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

Boundless Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Boundless Bio Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Friday, May 8, 2026
Conference Call Time
7:00AM ET

Boundless Bio Earnings Headlines

Now that SpaceX is public, buy this ticker (no, not SpaceX or Tesla)
The SpaceX IPO wasn't the big trade - according to Larry Benedict, founder of The Opportunistic Trader, it was the trigger. Benedict, who delivered a 279% return on cash in 2025 across a 20-year winning streak, says the listing launched what he calls the 'Final Phase of Elon's Master Plan.' He's identified one specific ticker - not SpaceX, Tesla, or any Elon-affiliated company - that he believes could see billions in inflows as this phase unfolds. He calls it his trade of the year.tc pixel
See More Boundless Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Boundless Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Boundless Bio and other key companies, straight to your email.

About Boundless Bio

Boundless Bio (NASDAQ:BOLD) Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

View Boundless Bio Profile